on The Vanguard Group, Inc. (isin : US12572Q1058)
The Vanguard Group Discloses Position in Avadel Pharmaceuticals
The Vanguard Group, Inc. has made an opening position disclosure regarding its interests in Avadel Pharmaceuticals plc. As of November 25, 2025, Vanguard holds a significant stake in Avadel, with 5,576,808 ordinary shares representing 5.73% of the company. This disclosure is compliant with the Irish Takeover Panel rules under the Panel's Act of 1997.
The disclosure revealed a recent purchase of 4,554 US$0.01 ordinary shares at a unit price of 22.93 USD. No dealings were reported in cash-settled or stock-settled derivatives involving Avadel's securities.
No indemnity or option arrangements have been reported, and there are no agreements influencing voting rights or future transactions involving Avadel's securities.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all The Vanguard Group, Inc. news